View Fisher & Paykel Healthcare's Dividend History, Capital Management Policy and Dividend Reinvestment Plan.
If you require a dividend statement, please contact our Share Registrar using the contact details below:
LINK Market Services Limited Level 30, PwC Tower 15 Customs Street West Auckland 1010 PO Box 91976 Auckland 1142
Investor enquiries: +64 9 375 5998 Fax: +64 9 375 5990 enquiries@linkmarketservices.co.nz
LINK Market Services Limited Level 12, 680 George Street Sydney, NSW 2000 Locked Bag A14 Sydney South NSW 1235
Investor enquiries: +61 2 8280 7111 Fax: +61 2 9287 0303 registrars@linkmarketservices.com.au
In accordance with the company’s capital management policy, the company’s directors have approved a final dividend of 17.5 cents per share, an increase of 3% on the interim dividend last year. The interim dividend, carrying full New Zealand imputation credit, will be paid on 21 December 2022 with a record date of 9 December 2022.
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment